| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study is developing a novel treatment for alveolar soft part sarcoma, which is a rare malignant tumor. We identified multiple tyrosine kinases, which are related to the mechanism of tumor development. We pre-clinically examined anti-tumor effect against alveolar soft part sarcoma by using tyrosine kinase inhibitor. As a result, Cabozantinib and Dasatinib showed significant anti-tumor activity both in vitro and in vivo. These results indicate that identified tyrosine kinases in this study are promising therapeutic target and these tyrosine kinase inhibitors can be a potent new therapeutic option.
|
